Sinovac and Parenteral Biotech Enter Supply and Distribution Agreement for India
Sinovac Biotech, Ltd. (Beijing, China), a vaccine manufacturer, has signed an exclusive license, supply, and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company.
Sinovac Biotech, Ltd. (Beijing, China), a vaccine manufacturer, has signed an exclusive license, supply, and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. According to the agreements, Parenteral is authorized to register, supply, and distribute Sinovac’s Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government and private market in India. The registration process currently is ongoing in India.
Parenteral intends to apply to the Drug Controller General of India for the import approval for the vaccines. The volume, delivery schedule, and other specific details about how Sinovac’s vaccines may be marketed and supplied to the government of India and the private market in India have not been determined.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
